Literature DB >> 3330516

The metabolism and fate of closantel (Flukiver) in sheep and cattle.

M Michiels1, W Meuldermans, J Heykants.   

Abstract

Closantel was reasonably well absorbed in sheep and cattle. After oral (10 mg/kg) or parenteral (5 mg/kg) administration, similar peak times (8-48 h) and peak plasma levels (45-55 micrograms/mL) are observed. Plasma level-time curves are superimposable for either route and increase linearly with the dose. The elimination half-life of closantel is 2 to 3 weeks. The relative bioavailability of 50% of oral closantel can partly be explained by incomplete absorption. Experiments in sheep with 14C-closantel revealed that the plasma radioactivity is almost exclusively due to the unmetabolized drug, metabolites accounting for less than 2%. At least 80% of the dose was excreted with the feces over the investigational period of 8 weeks, and less than 0.5% with the urine. Closantel was only poorly metabolized. Over 90% of the fecal radioactivity was due to the parent compound. Two monoiodoclosantel isomers were the only fecal metabolites detected with radio-HPLC. The distribution of closantel to tissues was limited by its high protein binding. Closantel bound strongly (greater than 99.9%) and almost exclusively to plasma albumin. Accordingly, tissue concentrations were many times lower than the corresponding plasma levels. Residual radioactivity in sheep in all tissues but liver was entirely due to closantel. About 30% to 40% of the liver radioactivity could be attributed to monoiodoclosantel. In both sheep and cattle, residual tissue concentrations decline parallel to the plasma concentrations. Consequently, the plasma kinetics of closantel reliably reflect its depletion from tissues. Independently of the dosing scheme and route of administration, the maximum daily intake by the consumer was always below the acceptable daily intake within 4 weeks after the last dose.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3330516     DOI: 10.3109/03602538708998307

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  8 in total

1.  Fasciola hepatica: effects of the fasciolicide clorsulon in vitro and in vivo on the tegumental surface, and a comparison of the effects on young- and old-mature flukes.

Authors:  M Meaney; I Fairweather; G P Brennan; L S L McDowell; A B Forbes
Journal:  Parasitol Res       Date:  2003-08-22       Impact factor: 2.289

2.  A scanning electron microscope study on the route of entry of clorsulon into the liver fluke, Fasciola hepatica.

Authors:  M Meaney; S Haughey; G P Brennan; I Fairweather
Journal:  Parasitol Res       Date:  2004-12-10       Impact factor: 2.289

3.  Closantel Retinal Toxicity: Case Report and Literature Review.

Authors:  Sepideh Ghods; Elias Khalili Pour; Hamid Riazi-Esfahani; Hooshang Faghihi; Bahman Inanloo
Journal:  Case Rep Ophthalmol Med       Date:  2021-05-21

4.  First report of closantel treatment failure against Fasciola hepatica in cattle.

Authors:  Adam Novobilský; Johan Höglund
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2015-08-28       Impact factor: 4.077

5.  Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus.

Authors:  Rajmohan Rajamuthiah; Beth Burgwyn Fuchs; Elamparithi Jayamani; Younghoon Kim; Jonah Larkins-Ford; Annie Conery; Frederick M Ausubel; Eleftherios Mylonakis
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

6.  Dual protonophore-chitinase inhibitors dramatically affect O. volvulus molting.

Authors:  Major Gooyit; Nancy Tricoche; Sara Lustigman; Kim D Janda
Journal:  J Med Chem       Date:  2014-06-20       Impact factor: 7.446

7.  Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii.

Authors:  Thien B Tran; Soon-Ee Cheah; Heidi H Yu; Phillip J Bergen; Roger L Nation; Darren J Creek; Anthony Purcell; Alan Forrest; Yohei Doi; Jiangning Song; Tony Velkov; Jian Li
Journal:  J Antibiot (Tokyo)       Date:  2015-12-16       Impact factor: 2.649

8.  Reversible blindness in a patient with closantel toxicity.

Authors:  Karthik Kumar; Chitaranjan Mishra; Rupa Anjanamurthy; Naresh Babu Kannan; Kim Ramasamy
Journal:  Indian J Ophthalmol       Date:  2019-10       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.